Novellia Launches AI-Powered Research Initiative to Transform Breast Cancer Care

Novellia, Inc. has announced the launch of Project EVEREST, a cross-industry initiative designed to improve adherence to clinical guidelines in breast cancer treatment. The groundbreaking project brings together leading researchers, clinicians, and biopharmaceutical companies including Daiichi Sankyo, Genentech, and AstraZeneca to address barriers preventing consistent cancer care across healthcare settings.

As the first AI-enabled, patient-permissioned longitudinal registry focused on real-world treatment adherence in breast cancer, Project EVEREST represents a new standard for quality improvement research. The initiative leverages Novellia's proprietary AI platform to create a comprehensive patient registry by unifying complex medical histories across NCI-designated cancer centers, lab centers, and regional health systems.

Researchers from the University of Alabama at Birmingham (UAB) will analyze these unified datasets to uncover patterns in care delivery and identify gaps in the application of current breast cancer treatment guidelines. The analysis will deliver targeted recommendations for improving treatment consistency and patient outcomes.

"The key question we aim to answer is what systemic and clinical factors are preventing patients from receiving the most current, evidence-based care for breast cancer," said Dr. Humaira Sarfraz, Assistant Professor of Medicine and clinician-educator in the Division of Hematology and Oncology at the UAB Medical Center. "The field of oncology is moving at an unprecedented rate, and next-generation, AI-enabled data platforms open up possibilities for us to drive better outcomes for patients by examining real-world data along with patient medical histories and pinpoint where care may fall short in ways that were previously impossible or time prohibitive."

The program will enroll early and metastatic breast cancer patients, including those with HER2+ and HR+/HER2- subtypes. Over a 24-month period, researchers will aggregate and analyze hundreds of thousands of retrospective and prospective patient records to identify trends and deviations from established treatment guidelines. In Phase 2, researchers will deliver tailored, evidence-based interventions to support health systems and community oncologists in optimizing care delivery.

"When biopharma teams face questions others can't answer, they turn to Novellia for our unique ability to build full, sequential patient stories that reveal hidden insights traditional data providers aren't equipped to find. Project EVEREST builds on our reputation as the only data partner that goes deep enough to solve the toughest challenges in healthcare," said Shashi Shankar, CEO and co-founder of Novellia. "In the past, building these sorts of longitudinal datasets would have cost tens of millions of dollars and required several months of manual data processing by teams of clinical abstractors. By using AI to autonomously unify fragmented health histories and surface critical blind spots missed by traditional real-world data solutions, we're closing the gap between data and decisions. Project EVEREST brings together biopharma leaders, top researchers, and our AI-enabled platform to deliver a scalable model for evidence-based care improvement in breast cancer—and a roadmap for addressing care variation across other complex diseases."

Click here for the original news story.